Engdahl E, et al. Serological response against HHV-6A is associated with increased risk for multiple sclerosis. Abstract 222. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024